Chemotherapy-induced Neutropenia
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Neutropenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-02-03Clinical Trial Update: Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel [Phase 2, Phase 3]
Clinical trial update for Balugrastim (Neugranin) in breast cancer patients receiving doxorubicin/docetaxel; Phase 2/3 completed with result…
-
CLINICAL_TRIALS trial_result · 2022-10-21Clinical Trial Update: Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients [Phase 3]
Phase 3 clinical trial evaluating lithium for chemotherapy-induced neutropenia in breast cancer patients has completed.
-
CLINICAL_TRIALS trial_result · 2022-07-07Clinical Trial Update: Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma [Phase 2]
Phase 2 clinical trial update for Mecapegfilgrastim (PEG-G-CSF) as prophylaxis for chemotherapy-induced neutropenia in lymphoma patients.
-
FDA approval · 2022-05-26FDA Approved: FYLNETRA — Original Application (Amneal Pharmaceuticals LLC)
FDA approves FYLNETRA (pegfilgrastim) from Amneal as an original biologics license application to help reduce the duration of neutropenia in…
-
FDA approval · 2022-02-25FDA Approved: RELEUKO — Original Application (Amneal Pharmaceuticals LLC)
FDA approved RELEUKO (filgrastim) from Amneal Pharmaceuticals LLC under an Original Application (BLA 761082).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-07-08Clinical Trial Update: Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
Completed feasibility trial evaluating monitoring of health data in pediatric patients undergoing chemotherapy.
-
FDA approval · 2021-06-07FDA Approved: UDENYCA — Supplemental Application (Accord BioPharma, Inc.)
FDA approved a supplemental application for UDENYCA (pegfilgrastim-cbqv) from Accord BioPharma, Inc., under the biosimilars program.
-
CLINICAL_TRIALS trial_result · 2021-01-15Clinical Trial Update: Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia [Phase 3]
Phase 3 trial update comparing plinabulin to pegfilgrastim for prevention of TAC-induced neutropenia in chemotherapy patients; current statu…
-
FDA approval · 2020-06-10FDA Approved: NYVEPRIA — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved NYVEPRIA (pegfilgrastim-APGF) from Pfizer in an original biologics application, establishing a pegfilgrastim biosimilar therapy…
-
CLINICAL_TRIALS trial_result · 2020-03-13Clinical Trial Update: Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients [Phase 4]
Phase 4 trial updating timing of granulocyte colony-stimulating factor (G-CSF) after chemotherapy in pediatric patients to assess outcomes.
-
FDA approval · 2020-02-12FDA Approved: UDENYCA — Supplemental Application (Accord BioPharma, Inc.)
FDA approved a supplemental Biologics License Application for UDENYCA (pegfilgrastim-cbqv) submitted by Accord BioPharma, Inc., expanding it…
-
CLINICAL_TRIALS trial_result · 2020-01-18Clinical Trial Update: Plinabulin iv Solution in Prevention of TAC Induced Neutropenia [Phase 2]
Phase 2 clinical trial update for Plinabulin intravenous solution in preventing TAC-induced neutropenia has completed.
-
FDA approval · 2019-10-17FDA Approved: UDENYCA — Supplemental Application (Accord BioPharma, Inc.)
FDA approved a supplemental application for UDENYCA (pegfilgrastim-CBQV) submitted by Accord BioPharma, Inc. This action approves changes as…
-
CLINICAL_TRIALS trial_result · 2019-10-08Clinical Trial Update: Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer [Phase 3]
Phase 3 trial update evaluating Granulocyte Colony Stimulating Factor for prevention of febrile neutropenia in epithelial ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2019-09-13Clinical Trial Update: Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients [Phase 2]
Phase 2 trial update for a recombinant human serum albumin/G-CSF fusion protein in breast cancer patients undergoing chemotherapy, completed…
-
CLINICAL_TRIALS trial_result · 2019-06-28Clinical Trial Update: Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study
A real-life study evaluating the biosimilar Nivestim® for preventing chemotherapy-induced neutropenia; the trial has been terminated with re…
-
FDA approval · 2019-04-16FDA Approved: UDENYCA — Supplemental Application (Accord BioPharma, Inc.)
FDA approved a supplemental application for UDENYCA (pegfilgrastim-cbqv) from Accord BioPharma, authorizing a new or expanded use for the pr…
-
CLINICAL_TRIALS trial_result · 2019-02-19Clinical Trial Update: Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
A real-world study evaluating PEG-rhG-CSF for the prevention of chemotherapy-induced neutropenia and associated myelosuppression.
-
CLINICAL_TRIALS trial_result · 2019-02-12Clinical Trial Update: Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia [Phase 2]
A randomized Phase 2 trial comparing ANF-RHO to Neulasta for chemotherapy-induced neutropenia has been terminated. The study was a dose-find…
-
CLINICAL_TRIALS trial_result · 2019-01-07Clinical Trial Update: G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients [Phase 4]
Phase 4 trial update evaluating G-CSF for prevention of febrile neutropenia in gynecologic cancer patients undergoing chemotherapy.
-
FDA approval · 2018-11-02FDA Approved: UDENYCA — Original Application (Accord BioPharma, Inc.)
FDA approved UDENYCA (pegfilgrastim-cbqv) as an original biologics license application for reducing the duration of neutropenia in patients …
-
CLINICAL_TRIALS trial_result · 2018-09-18Clinical Trial Update: Pegteograstim in Children With Solid Tumors [Phase 2]
Phase 2 clinical trial update for Pegteograstim in pediatric patients with solid tumors undergoing chemotherapy.
-
FDA approval · 2018-07-31FDA Approved: GRANIX — Supplemental Application (Cephalon, LLC)
FDA approved a supplemental application for GRANIX (TBO-FILGRASTIM) submitted by Cephalon, LLC.
-
CLINICAL_TRIALS trial_result · 2017-11-24Clinical Trial Update: Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia [Phase 2]
Phase IIa trial results assess the efficacy and safety of Myelo001 for chemotherapy-induced neutropenia with completed status.
-
CLINICAL_TRIALS research · 2017-08-18Clinical Trial Update: Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer [Phase 1]
Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics/pharmacodynamics of GW003 in breast cancer patients, with c…